Diabetes has many associated co‐morbidities that involve ischemia (e.g., peripheral vascular disease), but therapeutic angiogenesis is more difficult to stimulate in diabetes.[55, 56, 57, 58] An envisioned clinical translation of the SRDD system is to deliver cationic VEGF locally in a stimuli‐responsive spatiotemporal manner to pre‐vascularize an implant site prior to islet transplantation to improve islet viability. The gene discussed is VEGFA; the disease is peripheral vascular disease.